Shares of Novo Nordisk A/S ( NYSE: NVO) dropped 1.9%today, closing at $48.25, just a whisker above the 52-week low of $45.05. Sometimes we see a divergence in share price and sentiment, but with Novo Nordisk they're actually well correlated. Discussion on Reddit has remained uniformly bearish throughout November. Novo Nordisk is trading more than 50% below its 52-week high, a stunning collapse for a company that was once viewed as the premier play on the obesity treatment revolution.
Despite the hype surrounding artificial intelligence, C3.ai seems stuck in neutral, failing to capitalize on the sector's explosive growth. The old Wall Street adage, "buy the rumor, sell the news," doesn't quite fit here. With C3.ai, the strategy appears to be sell the rumor, sell the news, and, frankly, just sell the stock. The company's inability to turn AI enthusiasm into sales or profits, coupled with leadership turmoil, paints a grim picture for its future.
